

**Aus dem Institut für Molekularbiologie und Biochemie**  
des Fachbereiches Humanmedizin  
der Freien Universität Berlin  
(Abteilung Biochemie Leiter: Prof. Dr. Med. W. Reutter)

**Immunostimulation and Induction of Apoptosis of  
Tumour Cells by Effective Compounds from  
*Ganoderma lucidum* and *Polygonum cuspidatum***

Inaugural-Dissertation  
zur Erlangung des Doktorwürde  
am Fachbereich Humanmedizin  
der Freien Universität Berlin

Vorgelegt von  
Tang, Qingjiu  
aus Shanghai, P.R. China

Berlin 2002

**1. Gutachter: Prof. Dr. Werner Reutter**

**2. Gutachter: Prof. Dr. Christoph C. Geilen**

**Tag der Promotion: 5. Nov. 2002**

<b>Contents</b>		<b>Page</b>
Abbreviation		
<b>1.</b>	<b>Introduction</b>	<b>1</b>
1.1.	Natural products in anticancer therapy	1
1.2.	Chemoprevention	2
1.3.	Immunotherapy	2
1.4.	Traditional Chinese medicine (TCM) is a shortcut way	4
1.5.	The biological functions of <i>Ganoderma lucidum</i> and <i>Polygonum cuspidatum</i> .	4
1.5.1.	<i>Ganoderma lucidum</i>	4
1.5.1.1.	Immunomodulating activity	4
1.5.1.2.	Anticancer activity	5
1.5.1.3.	Anti virus activity	6
1.5.1.4.	Other functions	6
1.5.2.	<i>Polygonum cuspidatum</i>	6
1.5.2.1.	Anticancer activity	6
1.5.2.2.	Healing of burn	7
1.5.2.3.	Other functions	7
1. 6.	The background of the work	7
1.7.	Aim of this work	8
<b>2.</b>	<b>Material and Methods</b>	<b>9</b>
2.1.	Materials	9
2.1.1.	Reagents	9
2.1.2.	Antibody	10
2.1.3.	Kit	10
2.1.4.	Medium	10
2.1.5.	Crude extracts	11
2.1.6.	Cell lines	11
2.1.7.	Animals	11

2.2.	Methods	11
2.2.1.	Cell preparation and cell culture	11
2.2.1.1.	Tumour cell lines	11
2.2.1.2.	Preparation of lymphocytes from mouse spleens	12
2.2.1.3.	Preparation of lymphocytes from mouse spleens of sarcoma-bearing Balb <sup>c</sup> mice (TMSLs)	12
2.2.1.4.	Separation of B cells from mouse spleen lymphocytes by magnetic cell sorting	12
2.2.1.5.	Preparation of bone marrow-derived macrophages (BMMs)	13
2.2.1.6.	Preparation of bone marrow-derived macrophages from sarcoma-bearing Balb <sup>c</sup> mice (TBMMs)	13
2.2.2.	Separation, purification and identification	13
2.2.2.1.	Separation and purification of GLIS from <i>Ganoderma lucidum</i> (GL)	13
2.2.2.2.	Determination of purity and estimation of Mr of the active fraction GLIS by gel-filtration HPLC	14
2.2.2.3.	Quantitation of carbohydrate content in active fraction GLIS by DIG Glycan Detection Kit	14
2.2.2.4.	Polymyxin B treatment of GLIS	14
2.2.2.5.	Treatment of GLIS with Pronase E and NaIO <sub>4</sub>	14
2.2.2.6.	Separation and purification of the active compound from <i>Polygonum cuspidatum</i>	15
2.2.2.7.	Identification of HZ-3-1-b by thin layer chromatography (TLC)	15
2.2.2.8.	Identification of HZ-3-1-b by high performance liquid chromatography (HPLC)	15
2.2.3.	Bioassay	15
2.2.3.1.	Determination of activation by the Alamar Blue Assay	15
2.2.3.2.	Quantification of cytokines IL-1 $\beta$ and TNF- $\alpha$	16
2.2.3.3.	Measurement of nitric oxide	16
2.2.3.4.	Determination of immunoglobulin production	16
2.2.4.	Phagocytosis assay	17

2.2.5.	Macrophages-mediated anti-tumour activity	17
2.2.6.	Analysis of activation and the change of subpopulation of lymphocytes after stimulation by active fractions using flow cytometry	17
2.2.7.	Response of macrophage $\beta$ -glucan, mannose receptor antagonist and anti-CD14 Ab to GLIS	18
2.2.8.	Measurement of binding of GLIS to macrophage surface	18
2.2.9.	B cell survival assay	18
2.2.10.	B cells co-cultured with macrophages or supernatants (SN) of macrophages	18
2.2.11.	Inhibition of the proliferation of different tumour cell lines	19
2.2.12.	Identification of apoptosis of tumour cells by annexin V-FITC Conjugate under fluorescence microscopy	19
2.2.13.	Quantification of apoptosis by flow cytometry using propidium iodide staining method	19
2.2.14.	Affinity chromatography	20
2.2.15.	Mass spectrometry analysis of the binding protein	20
2.2.16.	GAPDH activity assay	21
<b>3.</b>	<b>Results</b>	<b>22</b>
3.1.	Immunostimulation and characterization of the active compound GLIS from <i>Ganoderma lucidum</i>	22
3.1.1.	Activation of macrophages by GLIS	22
3.1.1.1.	Activation of bone marrow-derived macrophages (BMMs) by Different fungi crude extracts and by GLIS	22
3.1.1.2.	Activation of macrophages from normal mice (BMMs) and tumour mice (TBMMs) by GLIS	23
3.1.1.3.	Increase of interleukin-1 $\beta$ (IL-1 $\beta$ and tumor necrosis factor- $\alpha$ (TNF- $\alpha$ ) secretion of BMMs and TBMMs stimulated by GLIS	24
3.1.1.4.	Production of reactive nitrogen intermediates (RNI) by BMMs and TBMMs after stimulation with GLIS	25
3.1.1.5.	Increase of phagocytosis of BMMs and TBMMs after stimulation	

	by GLIS	25
3.1.1.6.	Tumor cytotoxicity of macrophages triggered by GLIS	27
3.1.2.	Activation and stimulation of B cells by GLIS	27
3.1.2.1.	Proliferation of B cells stimulated by GLIS	27
3.1.2.2.	Analysis of activation and proliferation of B cells stimulated by GLIS	29
3.1.2.3.	Secretion of immunoglobulin by MSLs and B cells after stimulation with GLIS	30
3.1.2.3.1.	Secretion of IgM and IgG by MSLs after stimulation by GLIS	30
3.1.2.3.2.	Secretion of IgM and IgG by B cells after stimulation by GLIS	30
3.1.3.	Interaction of B cells and macrophages after stimulation with GLIS	31
3.1.3.1.	Increase of survival of B cells in presence of macrophages after stimulation with GLIS	31
3.1.3.2.	Secretion of IgM by B cells in presence of macrophages after stimulation with GLIS	32
3.1.3.3.	Effect of IL-6 or supernatants of macrophages on the B cell	33
3.1.4.	B cells from tumour-bearing mice (TMSBs) stimulated by GLIS	34
3.1.4.1.	Proliferation and activation of TMSBs after stimulation by GLIS	34
3.1.4.2.	Production of IgM by TMSLs and TMBS after stimulation by GLIS	36
3.1.5.	IgM secretion of normal mice stimulated by GLIS <i>in vivo</i>	37
3.1.6.	Characterization of the active fraction GLIS	37
3.1.6.1.	Comparison of the properties of GLIS with LPS	37
3.1.6.2.	Structural analysis of the functional compound of GLIS	40
3.1.6.3.	Reduction of GLIS activity after digestion of GLIS with $\beta$ -1,3-glucanase	40
3.1.6.4.	Purification and determination of the molecular weight of GLIS fraction using gel-filtration HPLC	41
3.1.7.	Investigation of the mechanism of action of the active fraction GLIS	43
3.1.7.1.	Binding of FITC-GLIS to macrophages	43
3.1.7.2.	Inhibition of soluble $\beta$ -glucan-, mannose- receptor antagonist and anti-CD14 antibody on the activity of GLIS	43
3.2.	Induction of apoptosis of tumour cells by compounds from <i>Polygonum cuspidatum</i>	44

3.2.1.	Inhibition of proliferation and induction of apoptosis of tumour cells by <i>Polygonum cuspidatum</i>	44
3.2.1.1.	Inhibition of proliferation of SW620 cells by fractions and subfractions of <i>Polygonum cuspidatum</i>	44
3.2.1.2.	Inhibition of proliferation of different tumour cell lines by the active fraction HZ-3-1-b	46
3.2.1.3.	Identification of apoptosis of SW620 cells induced by HZ-3-1-b	46
3.2.1.4.	Analysis of DNA fragmentation of SW620 cells after treatment with HZ-3-1-b	46
3.2.1.5.	Influence of HZ-3-1-b on cell cycle of SW620 cells	50
3.2.2.	Separation, purification and identification of the active compound from the crude extract of <i>polygonum cuspidatum</i> comparison with resveratrol	51
3.2.2.1.	Fractionation of HZ by different methods	51
3.2.2.2.	Identification of active compound HZ-3-1-b	53
3.2.3.	Binding of resveratrol (HZ-3-1-b) to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and inhibition of resveratrol on GAPDH enzyme activity	55
3.2.3.1.	SDS-PAGE analysis of affinity purified sample by resveratrol-conjugated affinity chromatography	55
3.2.3.2.	Identification of resveratrol-binding protein by MALDI-TOF Mass spectrometry	55
3.2.3.3.	Inhibition of the GAPDH enzyme activity by resveratrol	56
<b>4.</b>	<b>Discussion</b>	<b>58</b>
4.1.	Bioassay-guided fractionation of traditional Chinese medicine	58
4.2.	Anti-tumour activities of GLIS	58
4.3.	GLIS selectively activates B cells and macrophages but not T cells	60
4.4.	Characterization of active fraction GLIS	61
4.5.	Interaction of B cells and macrophages	61
4.6.	The receptor of GLIS	62
4.7.	Chemoprevention of HZ-3-1-b	63

2.3.	Inhibition of the enzyme activity Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by resveratrol	64
<b>5.</b>	<b>Summary</b>	66
<b>6.</b>	<b>Reference</b>	68
	Publication	80
	Curriculum	81
	Acknowledgements	82

# Appendix

## Abbreviations

Ara	Arabinose
BMMs	Bone marrow-derived macrophages
CD	Cluster of differentiation
DEAE	Diethylaminoethyl
DMSO	Dimethylsulfoxide
ELISA	Enzyme-linked immunosorbent assay
FACS	Fluorescence-activated cell sorting
FCS	Fetal calf serum
FITC	Fluorescein isothiocyanate
Fuc	Fucose
GAL	Galactose
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
G-3-P	Glyceraldehyde-3-phosphate
GalNAc	N-Acetylgalactosamine
GlcNAc	N-Acetylglucosamine
Glu	Glucose
HPLC	High performance liquid chromatography
HSH	Crude extract from <i>Grifola frondosa</i>
HT	Crude extract from <i>Hericium erinaceum</i>
HZ	Crude extract from <i>Polygonum cuspidatum</i>
IC50	50% of inhibition concentration
IL-1 $\beta$	Interleukin-1 $\beta$
kDa	Kilodalton
LC50	50% of lethal concentration
IgG	Immunoglobulin G
IgM	Immunoglobulin M
LPS	Lipopolysaccharide from <i>Escherichia coli</i> 0111:B4
LZ	Crude extracts from <i>Ganoderma lucidum</i>
LZSBS	Crude extracts from spore of <i>Ganoderma lucidum</i>
MACS	Magnetic cell sorting
MALDI-TOF-MS	Matrix-assisted laser desorption / ionization time-of-flight mass spectrometry
Man	Mannose
Mr.	Relative molecular weight

MSB	Mouse spleen B cell
MSL	Mouse spleen lymphocyte
NAD	Nicotinamide adenine dinucleotide
PBS	Phosphate buffer
PE	R-phycoerythrin
PHA	Phytohemagglutinin
PI	Propidium iodine
PMSF	Phenylmethylsulfonylfluoride
RNI	Reactive nitrogen intermediate
RNase A	Ribonuclease A
SDS	Sodium dodecylsulfate
TFA	Trifluoroacetic acid
TLC	Thin layer chromatography
TBMMs	Bone marrow-derived macrophages from tumour-bearing mice
TMSB	B lymphocytes from spleen of tumour-bearing mice
TMSL	Lymphocytes from spleen of tumour-bearing mice
TNF- $\alpha$	Tumour necrosis factor- $\alpha$
Tris	Tris-hydroxymethyl-aminomethane
YZ	Crude extract from <i>Coriolus versicolor</i>